<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01475877</url>
  </required_header>
  <id_info>
    <org_study_id>MAC-02-11</org_study_id>
    <nct_id>NCT01475877</nct_id>
  </id_info>
  <brief_title>Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy</brief_title>
  <official_title>Bromday (Bromfenac Ophthalmic Solution)0.09% QD vs Nevanac (Nepafenac Ophthalmic Suspension) 0.1% TID for Control of Pain and Epithelial Healing Post (PRK)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virdi Eye Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virdi Eye Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the effect of two topical non-steroidal antiinflammatory agents to
      control pain after photorefractive keratectomy (PRK) eye surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Post-PRK pain</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-PRK epithelial healing</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Nepafenac</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromfenac</intervention_name>
    <description>Bromfenac 0.09% 1 drop in study eyes q day</description>
    <arm_group_label>Nepafenac</arm_group_label>
    <other_name>Bromday</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients undergoing photorefractive keratectomy in both eyes
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female at least 18 years of age,

          -  no other ocular studies with 15 days prior to dosing,

          -  BCVA 20/200 or better,

          -  return for study visits and follow instructions from investigator and staff,

          -  self administer test article

        Exclusion Criteria:

          -  Ocular inflammation,

          -  hypersensitivity to bromfenac or nepafenac,

          -  any corneal pathology,

          -  have had radial keratotomy,

          -  corneal transplant or corneal refractive surgery in the last two years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Navaneet S Borisuth, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virdi Eye Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virdi Eye Clinic and Laser Vision Center</name>
      <address>
        <city>Rock Island</city>
        <state>Illinois</state>
        <zip>61201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2011</study_first_submitted>
  <study_first_submitted_qc>November 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2011</study_first_posted>
  <last_update_submitted>May 1, 2016</last_update_submitted>
  <last_update_submitted_qc>May 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bromfenac</keyword>
  <keyword>nepafenac</keyword>
  <keyword>PRK</keyword>
  <keyword>epithelial healing,</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nepafenac</mesh_term>
    <mesh_term>Bromfenac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>In the observational study conducted, there was no significant difference in pain levels or epithelial healing of post-photorefractive keratectomy patients who were treated with bromfenac 0.09% or nepafenac 0.1%</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

